Articles

Back to Articles

Rituximab Takes the Lead in Cancer Treatment

(Pub. 15th July, 2012)

 

Rituximab is in the group of medications known as monoclonal antibodies, which are designed to recognize certain proteins found on the surface of some lymphoma  cells. Once a monoclonal antibody recognizes the protein and gets a lock on it, the immune system is likely to be triggered to attack and destroy the cancer cells. This is particularly effective when Rituximab is used to treat either indolent or aggressive Non-Hodgkin's Lymphoma. In addition to being a formidable treatment for Non-Hodgkin's Lymphoma patients, people with CD20-positive Chronic Lymphocytic Leukemia (CLL) also benefit from treatment with Rituximab. When used in conjunction with the chemotherapeutic drugs Fludarabine and Cyclophosphamide, Rituximab works in tandem with these chemotherapy drugs, and together they target and attack the CLL cells. As the only treatment for rheumatoid arthritis (RA) that provides a significant period of symptom improvement, Rituximab is now considered to be an efficacious option for patients with RA. One course of treatments, encompassing two infusions of Rituximab leads to roughly six months of vast symptom improvement. By targeting B cells, Rituximab seeks to remedy the source of the cells believed to play an impressive role in the progress of RA. However, these three conditions are not the only ones Rituximab is effectual for. Patients with Wegener's Granulomatosis and Microscopic Polyangiitis can breathe a sign of relief for the advent of Rituximab. As the only FDA approved therapy, used adjunctively with glucocorticoids, Rituximab is a game changer for patients suffering from these forms of vasculitis that mainly affect the small blood vessels.

 Originally approved as a single agent treatment for relapsed indolent lymphoma in 1997, Rituximab began receiving notoriety after it's first groundbreaking study deemed "CHOP". The pivotal data gleaned from this study showed Rituximab to be a synergetic treatment alongside chemotherapy. The results from this study, which involved elderly patients with Diffuse Large B-cell Lymphoma, proved that the use of Rituximab elicited significant response rates from patients who received this unique drug. Treatment for patients with B-cell lymphoma today typically involve being dosed with Rituximab, along with other chemotherapeutic medications, due to it's consistent tolerability and effectiveness.

 Known as the brand name Rituxan, Rituximab superceded Avastin as the top selling cancer drug in the United States in 2011. Sales of rituxan, or Rituximab, rose eight percent, to six billion francs. This overthrow of Roche's leading cancer drug by Genentech has generated excitement in the pharmaceutical community. With principal patents expiring in the U.S. beginning in 2013, Rituximab is on track to becoming a generic boon for physicians and patients alike. New investigations are underway to determine the efficacy of Rituximab for treating lupus, multiple sclerosis and platelet disorders. Monoclonal Antibody therapies are now an integral part of both cancer treatment regimens and clinical trials. Researchers are excited about the future developments and challenges involving Rituximab as well as other novel forms of  immunotherapy.

YES Pharma is proud to be a leading supply source for Rituximab (CAS#: 174722-31-7) to several global pharmaceutical companies and academic research institutes, while recognizing that we play a significant part in promoting the struggle against different Cancer forms, including CLL, Non-Hodgkins Lymphoma, RA and Vasculitis. The Rituximab that YES Pharma supplies is intended for laboratory R&D use only.

References

Bloomberg Business
Businessweek.com
Gene.com
NCBI

 

  • Products covered by valid patents are not offered or supplied for commercial use.
  • Products currently covered by valid US patents are offered only for laboratory R&D use in accordance with 35 USC 271(e)+A13(1)
  • Any patent infringement and resulting liability is solely at buyers risk

 

Dun and Bradstreet